Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Medytox (Exclusive Right To Develop Neurotoxin Products)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Portfolio of rights to commercialize neurotoxin products. The portfolio provides exclusive rights, outside of Korea, and co-exclusive rights in Japan, to develop and commercialize certain neurotoxin product candidates including a potential liquid-injectable product.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Business Products and Services
Acquirer
Primary Office
  • 78, Gagni 1-Gil, Ochang-Eup
  • Cheongwon-Gu, Chungcheongbuk-Do
  • Cheongju, 363-883
  • South Korea

Medytox (Exclusive Right To Develop Neurotoxin Products) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Medytox (Exclusive Right To Develop Neurotoxin Products)‘s full profile, request access.

Request full access to PitchBook

Medytox (Exclusive Right To Develop Neurotoxin Products) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Medytox (Exclusive Right To Develop Neurotoxin Products)‘s full profile, request access.

Request full access to PitchBook